Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 13.725 -3.35% -0.48
FATE closed up 0.64 percent on Wednesday, December 4, 2019, on 3.72 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FATE trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -3.35%
MACD Bearish Signal Line Cross Bearish -3.35%
Bullish Engulfing Bullish -3.35%
Pocket Pivot Bullish Swing Setup -3.35%
Volume Surge Other -3.35%
Bollinger Band Squeeze Range Contraction -3.35%
Stochastic Reached Oversold Weakness -3.35%
BB Squeeze Started Range Contraction -3.35%
Outside Day Range Expansion -3.35%
Oversold Stochastic Weakness -3.35%

Older signals for FATE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Orphan Diseases Cord Blood Adult Stem Cell Induced Stem Cells Lysosomal Storage Disorders

Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 22.82
52 Week Low 11.0
Average Volume 692,567
200-Day Moving Average 17.4244
50-Day Moving Average 14.7257
20-Day Moving Average 14.5253
10-Day Moving Average 14.6645
Average True Range 0.8156
ADX 17.57
+DI 16.0658
-DI 20.7613
Chandelier Exit (Long, 3 ATRs ) 13.3432
Chandelier Exit (Short, 3 ATRs ) 15.0368
Upper Bollinger Band 15.4322
Lower Bollinger Band 13.6184
Percent B (%b) 0.32
BandWidth 12.487178
MACD Line -0.1147
MACD Signal Line -0.1045
MACD Histogram -0.0101
Fundamentals Value
Market Cap 588.08 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -14.79
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.32
Resistance 3 (R3) 15.31 14.92 15.13
Resistance 2 (R2) 14.92 14.64 14.93 15.07
Resistance 1 (R1) 14.56 14.46 14.74 14.57 15.01
Pivot Point 14.17 14.17 14.26 14.18 14.17
Support 1 (S1) 13.81 13.89 13.99 13.83 13.39
Support 2 (S2) 13.43 13.71 13.44 13.33
Support 3 (S3) 13.07 13.43 13.27
Support 4 (S4) 13.08